Logo image of CAMP

CAMP4 THERAPEUTICS CORP (CAMP) Stock Fundamental Analysis

NASDAQ:CAMP - US13463J1016 - Common Stock

1.56 USD
+0.01 (+0.65%)
Last: 8/25/2025, 8:07:46 PM
1.57 USD
+0.01 (+0.64%)
Pre-Market: 8/26/2025, 8:40:33 AM
Fundamental Rating

2

Taking everything into account, CAMP scores 2 out of 10 in our fundamental rating. CAMP was compared to 547 industry peers in the Biotechnology industry. While CAMP seems to be doing ok healthwise, there are quite some concerns on its profitability. CAMP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CAMP had negative earnings in the past year.
CAMP had a negative operating cash flow in the past year.
CAMP had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CAMP reported negative operating cash flow in multiple years.
CAMP Yearly Net Income VS EBIT VS OCF VS FCFCAMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

With a Return On Assets value of -100.00%, CAMP is not doing good in the industry: 75.87% of the companies in the same industry are doing better.
With a Return On Equity value of -127.50%, CAMP perfoms like the industry average, outperforming 40.77% of the companies in the same industry.
Industry RankSector Rank
ROA -100%
ROE -127.5%
ROIC N/A
ROA(3y)-54.3%
ROA(5y)-38.38%
ROE(3y)-82.87%
ROE(5y)-73.07%
ROIC(3y)N/A
ROIC(5y)N/A
CAMP Yearly ROA, ROE, ROICCAMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CAMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAMP Yearly Profit, Operating, Gross MarginsCAMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K 20K 30K

More info and screens

4

2. Health

2.1 Basic Checks

CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CAMP has about the same amount of shares outstanding.
Compared to 5 years ago, CAMP has more shares outstanding
CAMP has a better debt/assets ratio than last year.
CAMP Yearly Shares OutstandingCAMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CAMP Yearly Total Debt VS Total AssetsCAMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -7.43, we must say that CAMP is in the distress zone and has some risk of bankruptcy.
CAMP has a Altman-Z score of -7.43. This is in the lower half of the industry: CAMP underperforms 66.73% of its industry peers.
CAMP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CAMP's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. CAMP outperforms 48.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.43
ROIC/WACCN/A
WACC9.7%
CAMP Yearly LT Debt VS Equity VS FCFCAMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 5.59 indicates that CAMP has no problem at all paying its short term obligations.
The Current ratio of CAMP (5.59) is comparable to the rest of the industry.
A Quick Ratio of 5.59 indicates that CAMP has no problem at all paying its short term obligations.
CAMP has a better Quick ratio (5.59) than 60.33% of its industry peers.
Industry RankSector Rank
Current Ratio 5.59
Quick Ratio 5.59
CAMP Yearly Current Assets VS Current LiabilitesCAMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

CAMP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2147.83%.
The Revenue for CAMP has decreased by -97.99% in the past year. This is quite bad
The Revenue for CAMP have been decreasing by -70.90% on average. This is quite bad
EPS 1Y (TTM)-2147.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-169.57%
Revenue 1Y (TTM)-97.99%
Revenue growth 3Y-87.18%
Revenue growth 5Y-70.9%
Sales Q2Q%-97.57%

3.2 Future

The Earnings Per Share is expected to grow by 18.94% on average over the next years. This is quite good.
CAMP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 79.12% yearly.
EPS Next Y59.56%
EPS Next 2Y27.98%
EPS Next 3Y18.94%
EPS Next 5YN/A
Revenue Next Year1803.99%
Revenue Next 2Y85.7%
Revenue Next 3Y79.12%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CAMP Yearly Revenue VS EstimatesCAMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
CAMP Yearly EPS VS EstimatesCAMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CAMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CAMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAMP Price Earnings VS Forward Price EarningsCAMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAMP Per share dataCAMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as CAMP's earnings are expected to grow with 18.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.98%
EPS Next 3Y18.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CAMP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (8/25/2025, 8:07:46 PM)

Premarket: 1.57 +0.01 (+0.64%)

1.56

+0.01 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)N/A N/A
Inst Owners50.24%
Inst Owner Change-7.34%
Ins Owners3.31%
Ins Owner Change0%
Market Cap31.45M
Analysts87.27
Price Target14.62 (837.18%)
Short Float %2.1%
Short Ratio2.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.36%
Min EPS beat(2)9.55%
Max EPS beat(2)13.17%
EPS beat(4)2
Avg EPS beat(4)-581.47%
Min EPS beat(4)-2111.25%
Max EPS beat(4)13.17%
EPS beat(8)3
Avg EPS beat(8)-296.37%
EPS beat(12)5
Avg EPS beat(12)-221.4%
EPS beat(16)9
Avg EPS beat(16)-140.29%
Revenue beat(2)2
Avg Revenue beat(2)1704.66%
Min Revenue beat(2)144.61%
Max Revenue beat(2)3264.71%
Revenue beat(4)3
Avg Revenue beat(4)912.54%
Min Revenue beat(4)-100%
Max Revenue beat(4)3264.71%
Revenue beat(8)4
Avg Revenue beat(8)453.58%
Revenue beat(12)5
Avg Revenue beat(12)300.52%
Revenue beat(16)5
Avg Revenue beat(16)222.49%
PT rev (1m)0%
PT rev (3m)-24.56%
EPS NQ rev (1m)0.88%
EPS NQ rev (3m)14.72%
EPS NY rev (1m)1.05%
EPS NY rev (3m)16.49%
Revenue NQ rev (1m)25%
Revenue NQ rev (3m)-98.55%
Revenue NY rev (1m)19.73%
Revenue NY rev (3m)218.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.45
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)-28.26
EYN/A
EPS(NY)-2.24
Fwd EYN/A
FCF(TTM)-2.31
FCFYN/A
OCF(TTM)-2.28
OCFYN/A
SpS0.15
BVpS1.98
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100%
ROE -127.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.3%
ROA(5y)-38.38%
ROE(3y)-82.87%
ROE(5y)-73.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.95%
Cap/Sales 17.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.59
Quick Ratio 5.59
Altman-Z -7.43
F-Score4
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)41.56%
Cap/Depr(5y)49.13%
Cap/Sales(3y)88.82%
Cap/Sales(5y)55.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2147.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-169.57%
EPS Next Y59.56%
EPS Next 2Y27.98%
EPS Next 3Y18.94%
EPS Next 5YN/A
Revenue 1Y (TTM)-97.99%
Revenue growth 3Y-87.18%
Revenue growth 5Y-70.9%
Sales Q2Q%-97.57%
Revenue Next Year1803.99%
Revenue Next 2Y85.7%
Revenue Next 3Y79.12%
Revenue Next 5YN/A
EBIT growth 1Y-19.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.03%
EBIT Next 3Y-18.8%
EBIT Next 5YN/A
FCF growth 1Y10.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.02%
OCF growth 3YN/A
OCF growth 5YN/A